Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid tumors
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2016
At a glance
- Drugs S 81694 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Servier
- 19 Dec 2016 Planned End Date changed from 30 Sep 2016 to 21 Oct 2019.
- 19 Dec 2016 Status changed from completed to recruiting.
- 01 Oct 2016 Status changed from recruiting to completed.